Ji XZ, Liu ZD, Ye YP, Li Q, Liu XJ, Zhou MH, Jin Y. Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report. World J Clin Cases 2024; 12(20): 4405-4411 [DOI: 10.12998/wjcc.v12.i20.4405]
Corresponding Author of This Article
Yi Jin, BMed, Attending Doctor, Department of Emergency Medicine, Lishui People's Hospital, No. 15 Mass Street, Liandu District, Lishui 323000, Zhejiang Province, China. 15990421805@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 16, 2024; 12(20): 4405-4411 Published online Jul 16, 2024. doi: 10.12998/wjcc.v12.i20.4405
Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report
Xing-Zu Ji, Zhong-Da Liu, Yi-Ping Ye, Quan Li, Xiao-Jing Liu, Min-Hua Zhou, Yi Jin
Xing-Zu Ji, Zhong-Da Liu, Quan Li, Xiao-Jing Liu, Min-Hua Zhou, Department of Respiratory and Critical Care Medicine, Lishui Hospital of Traditional Chinese Medicine, Lishui 323000, Zhejiang Province, China
Yi-Ping Ye, Traditional Chinese Medicine Oncology, Lishui Hospital of Traditional Chinese Medicine, Lishui 323000, Zhejiang Province, China
Yi Jin, Department of Emergency Medicine, Lishui People's Hospital, Lishui 323000, Zhejiang Province, China
Co-first authors: Xing-Zu Ji and Zhong-Da Liu.
Author contributions: Ji XZ designed the study; Liu ZD, Ye YP, Li Q, Liu XJ, and Zhou MH performed the data collection and analyzed the data; Jin Y wrote the manuscript; All authors reviewed the manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and all accompanying images.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi Jin, BMed, Attending Doctor, Department of Emergency Medicine, Lishui People's Hospital, No. 15 Mass Street, Liandu District, Lishui 323000, Zhejiang Province, China. 15990421805@163.com
Received: April 7, 2024 Revised: May 23, 2024 Accepted: June 3, 2024 Published online: July 16, 2024 Processing time: 83 Days and 13.7 Hours
Abstract
BACKGROUND
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of patients with Epidermal growth factor receptor (EGFR) sensitive mutations in non-small cell lung cancer (NSCLC).
CASE SUMMARY
A 67-year-old female patient in advanced lung adenocarcinoma suffered from drug resistance after EGFR-TKIs treatment. Secondary pathological tissue biopsy confirmed squamous cell carcinoma (SCC) transformation. Patients inevitably encountered drug resistance issues after receiving EGFR-TKIs treatment for a certain period of time, while EGFR-TKIs can significantly improve the survival of patients with EGFR-sensitive mutations in NSCLC. Notably, EGFR-TKIs resistance includes primary and acquired. Pathological transformation is one of the mechanisms of acquired resistance in EGFR-TKIs, with SCC transformation being relatively rare. Our results provide more detailed results of the patient’s diagnosis and treatment process on SCC transformation after EGFR-TKIs treatment for lung adenocarcinoma.
CONCLUSION
Squamous cell carcinoma transformation is one of the acquired resistance mechanisms of EGFR-TKIs in advanced lung adenocarcinoma with EGFR mutations.
Core Tip: Patients inevitably encounter drug resistance after receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. EGFR-TKIs resistance included primary and acquired. Pathological transformation is one of mechanism of acquired resistance in EGFR-TKIs, with squamous cell carcinoma (SCC) transformation being relatively rare. This results provide more detailed results of the patients’ diagnosis and treatment process, alongside a review of literature on SCC transformation after EGFR-TKIs treatment for lung adenocarcinoma.
